Flow Enabled Synthesis of Multiresistant Drug ClofazimineTuesday, 26 March 2024 at 18:00 Add to Calendar ▼2024-03-26 18:00:002024-03-26 19:00:00Europe/LondonFlow Enabled Synthesis of Multiresistant Drug ClofazimineFlow Chemistry European Summit 2024 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com Drug resistance to tuberculosis is still one of the significant challenges worldwide. Clofazimine, which belongs to the riminophenazine (anti-biotic) class, is still one of the active drugs that are efficient against drug resistance M. Tuberculosis. Apart from this, it is also a WHO-approved drug for the treatment of leprosy (Hansen's Disease) and, at present, is under phase 2 clinical trial for its activity against the SARS-CoV-2 virus. Owing to its vast importance in clinical research, we have developed a continuous-flow mediated synthesis of clofazimine using readily available p-chloroaniline and 1-fluro-2-nitrobenzene. The target drug molecule was obtained from four consecutive chemical transformations with nominal reaction time and improved purity and yields when compared to the batch process. Moreover, the first two steps were also successfully telescoped under optimized reaction conditions. |